| Name | Daxdilimab |
|---|
| Description | Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research[1][2]. |
|---|---|
| Related Catalog | |
| References |
| No Any Chemical & Physical Properties |